Explore

Rapid ReadRapid Read
Diethyl Fumarate Shows Promise Against Drug-Tolerant Tuberculosis Persisters

Diethyl Fumarate Shows Promise Against Drug-Tolerant Tuberculosis Persisters

A study published in Frontiers in Cellular and Infection Microbiology indicates that diethyl fumarate (DEF) exhibits potent activity against differentially culturable Mycobacterium tuberculosis (Mtb) persisters. These persisters are drug-tolerant forms of Mtb that contribute to prolonged tuberculosis treatment and disease relapse. The research developed a workflow to evaluate drug candidates against these persisters, validating it with dimethyl fumarate (DMF) derivatives. While DMF and DEF inhibited Mtb growth, ethyl-3-benzoylacrylate (EBL) and methyl-trans-4-oxo-2-pentenoate (MTOP) demonstrated bactericidal activity against both Mtb and Mycobacterium abscessus (Mabs). The study found that DMF and DEF effectively eliminated DC Mtb within infected macrophages, suggesting their anti-persister activity is mediated through modulating the host immune response, particularly by inhibiting nitric oxide (NO) production, rather than solely through direct action on Mtb. This dual anti-inflammatory and anti-mycobacter...
Rapid ReadRapid Read
Biohub Secures $1.8 Billion for 'Virtual Biology' Initiative to Accelerate Scientific Discovery

Biohub Secures $1.8 Billion for 'Virtual Biology' Initiative to Accelerate Scientific Discovery

Biohub, a non-profit research organization founded by Meta CEO Mark Zuckerberg and Priscilla Chan, has secured $1.8 billion in funding for its 'Virtual Biology' initiative. This AI-powered open-source platform aims to create a 'world model' of biology to serve as a discovery engine for protein structure prediction, design, and broader biological insights. The substantial investment comes from a consortium of major entities, including the U.S. Department of Energy (DOE), the National Institutes of Health (NIH), Meta, Google DeepMind, and Isomorphic Labs. The funding is not solely cash; a significant portion comprises data, computational resources, and advanced measurement technology. Launched in April with initial funding of $500 million, the initiative seeks to enable scientists to conduct experiments digitally, thereby accelerating scientific discovery and understanding of diseases.
Rapid ReadRapid Read
New 'Mini-Brain' Model Advances Multiple Sclerosis Myelin Repair Research

New 'Mini-Brain' Model Advances Multiple Sclerosis Myelin Repair Research

Scientists have developed a 3D 'mini-brain' model from human stem cells, roughly the size of a grain of rice, to study multiple sclerosis (MS) related damage and repair. This model, detailed in a study published in Nature Neuroscience, incorporates human nerve cells, myelin-producing cells, and microglia, allowing researchers to observe how MS affects the nervous system and how the body attempts to repair itself. The team, led by Samantha Barton, PhD, an associate professor at the Florey Institute of Neuroscience and Mental Health in Australia, exposed these spheroids to a substance that causes demyelination, observing significant myelin destruction and fragmentation. Crucially, the model also demonstrated an early remyelination response, with newly generated oligodendrocytes forming myelin sheaths. As a proof of concept, the researchers tested clemastine fumarate, a drug currently in clinical trials for MS, and found it significantly increased new myelinating oligodendrocytes. This development offers a ne...
Rapid ReadRapid Read
NHLBI Mandates Justification for Animal Use in Research Grant Applications by 2027

NHLBI Mandates Justification for Animal Use in Research Grant Applications by 2027

The National Heart, Lung, and Blood Institute (NHLBI) will require all grant applications submitted from January 2027 onwards to include an explicit justification for the use of animal models. This justification, to be placed in the application's Abstract section, must explain why animal models are necessary and why alternative methods are inferior. This new requirement aligns with the National Institutes of Health's (NIH) broader initiative to accelerate efforts in replacing, reducing, and refining animal use in research through New Approach Methodologies (NAMs). The NIH's Unified Strategy, announced earlier this year, aims to prioritize human-based research, particularly for chronic health issues affecting Americans, while reducing reliance on animal models. The NHLBI supports this strategy and encourages the development and use of NAMs in heart, lung, blood, and sleep research, citing examples like 3D 'valve-like assembloids' from human stem cells and lung iPSCs resources.
TrendlineTrendline
Obatala Sciences Establishes First East Coast Operation in Charleston County, South Carolina

Obatala Sciences Establishes First East Coast Operation in Charleston County, South Carolina

Obatala Sciences Establishes First East Coast Operation in Charleston County, South Carolina
Rapid ReadRapid Read
U.S. Government and Tech Giants Invest $1.8 Billion in AI for Biological Research

U.S. Government and Tech Giants Invest $1.8 Billion in AI for Biological Research

The U.S. government, in collaboration with technology companies Meta Platforms and Alphabet, is partnering with the nonprofit Biohub to create extensive open datasets for training advanced AI models in biological research. This initiative has garnered a total investment of $1.8 billion. Meta Platforms, Google DeepMind, and drug discovery startup Isomorphic Labs are contributing $300 million. Concurrently, the Department of Energy is committing over $500 million across five years for laboratory measurement, modeling, and computation. The National Institutes of Health will coordinate existing repositories and open datasets, established with over $500 million in previous federal grants, which Biohub will standardize for AI model training. These new pledges build upon a prior $500 million investment made by Biohub in April. The project, known as the Virtual Biology Initiative, aims to observe and measure cellular responses to environmental changes across a vast range of conditions, far exceeding previous studi...
Rapid ReadRapid Read
New Materials Offer Innovative Strategies to Combat Antibiotic Resistance

New Materials Offer Innovative Strategies to Combat Antibiotic Resistance

Researchers are developing new materials and approaches to tackle antibiotic resistance, moving beyond traditional antibiotic development. One strategy involves modifying the surfaces of surgical implants, such as hip and knee replacements, to prevent bacterial colonization. The National Center for Metallurgical Research (CENIM-CSIC) in Spain has created a fluorinated titanium oxide layer with a tubular structure that reduces bacterial adhesion on prostheses. This surface can also release incorporated antibiotics, acting before an infection is established. Another approach, explored by Enrique Martínez Campos’s team at the Institute of Polymer Science and Technology in Madrid, involves designing polymeric surfaces with microscopic honeycomb-like patterns to alter bacterial adhesion. Additionally, Rosario Núñez, PhD, and her team at the Spanish National Research Council are investigating antimicrobial photodynamic therapy, using photosensitive molecules activated by light to destroy bacteria. Imma Ratera, P...
Rapid ReadRapid Read
Sugar-Rich Diets Exacerbate Antibiotic-Induced Gut Microbiome Disruption in Transplant Patients

Sugar-Rich Diets Exacerbate Antibiotic-Induced Gut Microbiome Disruption in Transplant Patients

A recent Nature study, tracking over 9,400 meals from hematopoietic cell transplantation (HCT) patients, revealed a link between sugar-rich diets and increased gut microbiome disruption when combined with antibiotic exposure. Researchers found that higher sugar intake during broad-spectrum antibiotic treatment was associated with a greater reduction in gut microbial alpha-diversity. This effect was particularly pronounced for every additional 100g of sweets consumed, leading to an estimated 24% further reduction in diversity. Mouse model experiments corroborated these findings, showing that sucrose supplementation after antibiotics increased the expansion of *Enterococcus faecium*, a key antibiotic-resistant pathogen, by 16.3-fold on day 3 and 33.4-fold on day 6 compared to antibiotic-treated mice without additional sugar. The study suggests that dietary sugars may favor the growth of opportunistic bacteria, weaken the protective effects of competing gut microbes, or alter host intestinal responses, thereb...
ReutersReuters
US government, Google join Zuckerberg-backed Biohub in $1.8 billion push for AI biology data

US government, Google join Zuckerberg-backed Biohub in $1.8 billion push for AI biology data

By Krystal Hu Oct 7 (Reuters) - The US government and tech heavyweights Meta Platforms and Google parent Alphabet are joining nonprofit Biohub to build open datasets to train AI models for biological reasearch, bringing total investment in the effort to $1.8 billion, Biohub said on Wednesday.
Rapid ReadRapid Read
H. pylori Stool PCR Test Offers Enhanced Accuracy and Antibiotic Resistance Profiling Over Antigen Tests

H. pylori Stool PCR Test Offers Enhanced Accuracy and Antibiotic Resistance Profiling Over Antigen Tests

Diagnostic testing for Helicobacter pylori (H. pylori) has advanced significantly, with stool antigen tests (SAT) and polymerase chain reaction (PCR) stool tests being two prominent non-invasive methods. While both use stool samples, they differ fundamentally in their detection mechanisms and diagnostic insights. Stool antigen tests identify H. pylori surface proteins, indicating active bacterial shedding. In contrast, PCR tests target and amplify specific genetic material (DNA) unique to the H. pylori genome. According to the National Institutes of Health (NIH), H. pylori affects about 50% of the global population and is a primary cause of chronic gastritis, peptic ulcer disease, and gastric cancer. Accurate diagnosis is crucial to prevent long-term complications and avoid unnecessary antibiotic treatments.
Rapid ReadRapid Read
Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies, a company focused on developing naturally modified mRNA medicines, has secured $47 million in financing. This funding includes a Series A round led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. The investment will support the advancement and scaling of Sensible's integrated mRNA technology, specifically its VECTOR™ platform. This platform aims to overcome limitations of conventional synthetic mRNA production by using living cells to produce naturally modified mRNA. The company's approach is designed to reduce immunogenicity, achieve high protein expression, and avoid double-stranded RNA (dsRNA) contamination, a common issue with synthetic mRNA. Sensible Biotechnologies plans to use this financing to scale up its VECTOR platform, expand its AI-enabled mRNA design and high-throughput screening capabilities, and develop clinical-grade manufacturing capabilities.
TrendlineTrendline
AstraZeneca Inaugurates New Global Strategic R Center in Kendall Square, Cambridge, Massachusetts

AstraZeneca Inaugurates New Global Strategic R Center in Kendall Square, Cambridge, Massachusetts

AstraZeneca Inaugurates New Global Strategic R Center in Kendall Square, Cambridge, Massachusetts